Smoking termination opportunity for in patients (STOP): Superiority of a course of varenicline tartrate plus counselling over counselling alone for smoking cessation: A 12-month randomised controlled trial for inpatients

Brian James Smith, Kristin Veronica Carson, Malcolm Philip Brinn, Nadina Ann Labiszewski, Matthew J. Peters, Robert Fitridge, Simon A. Koblar, Jim Jannes, Antony J. Veale, Sharon J. Goldsworthy, John Litt, David Edwards, Adrian Jeffrey Esterman

Research output: Contribution to journalLetterpeer-review

19 Citations (Scopus)


Rationale: Smoking cessation interventions in outpatient settings have been demonstrated to be cost effective. Given this evidence, we aimed to evaluate the effectiveness of varenicline tartrate plus Quitline-counselling compared with Quitline-counselling alone when initiated in the inpatient setting. Methods: Adult patients (18-75 years) admitted with a smoking-related illness to three hospitals, were randomised to receive either 12-weeks of varenicline tartrate plus Quitline-counselling, (n=196) or Quitline-counselling alone, (n=196), with 12-months follow-up. Results: For the primary analysis population (intention-to-treat), the proportion of subjects who remained continuously abstinent were significantly greater in the varenicline plus counselling arm (31.1%, n=61) compared with counselling alone (21.4%, n=42; RR 1.45, 95% CI 1.03 to 2.03, p=0.03). Conclusions: The combined use of varenicline plus counselling when initiated in the inpatient setting has produced a sustained smoking cessation benefit at 12-months follow-up, indicating a successful opportunistic treatment for smokers admitted with smoking related illnesses.

Original languageEnglish
Pages (from-to)485-486
Number of pages2
Issue number5
Publication statusPublished or Issued - May 2013

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this